ZHX2 Promotes HIF1α Oncogenic Signaling in Triple-negative Breast Cancer
Authors
Affiliations
Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease, which warrants the critical need to identify new therapeutic targets. We show that Zinc Fingers and Homeoboxes 2 () is amplified or overexpressed in TNBC cell lines and patients. Functionally, depletion of ZHX2 inhibited TNBC cell growth and invasion in vitro, orthotopic tumor growth, and spontaneous lung metastasis in vivo. Mechanistically, ZHX2 bound with hypoxia-inducible factor (HIF) family members and positively regulated HIF1α activity in TNBC. Integrated ChIP-seq and gene expression profiling demonstrated that ZHX2 co-occupied with HIF1α on transcriptionally active promoters marked by H3K4me3 and H3K27ac, thereby promoting gene expression. Among the identified ZHX2 and HIF1α coregulated genes, overexpression of , , , or could partially rescue TNBC cell growth defect by depletion, suggested that these downstream targets contribute to the oncogenic role of ZHX2 in an accumulative fashion. Furthermore, multiple residues (R491, R581, and R674) on ZHX2 are important in regulating its phenotype, which correspond with their roles on controlling ZHX2 transcriptional activity in TNBC cells. These studies establish that ZHX2 activates oncogenic HIF1α signaling, therefore serving as a potential therapeutic target for TNBC.
ZHX2 inhibits diabetes-induced liver injury and ferroptosis by epigenetic silence of YTHDF2.
Meng W, Li L Nutr Diabetes. 2025; 15(1):6.
PMID: 39987125 PMC: 11846978. DOI: 10.1038/s41387-025-00355-0.
Kanno H, Nakahara K, Yamada S, Fujii S, Murata H, Yamamoto T J Kidney Cancer VHL. 2025; 11(4):39-47.
PMID: 39850947 PMC: 11756601. DOI: 10.15586/jkcvhl.v11i4.355.
VHL suppresses UBE3B-mediated breast tumor growth and metastasis.
Wang S, Li H, Liu X, Yin T, Li T, Zheng M Cell Death Dis. 2024; 15(6):446.
PMID: 38914543 PMC: 11196597. DOI: 10.1038/s41419-024-06844-x.
Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma.
Liao C, Hu L, Zhang Q Nat Rev Urol. 2024; 21(11):662-675.
PMID: 38698165 DOI: 10.1038/s41585-024-00876-w.
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer.
Musleh Ud Din S, Streit S, Huynh B, Hana C, Abraham A, Hussein A Int J Mol Sci. 2024; 25(4).
PMID: 38396737 PMC: 10888675. DOI: 10.3390/ijms25042060.